2
|
Bindernagel R, Dazé R, Gibbs J, Hogan D. Erythematous, Telangiectatic Nodule within the Melomental Fold. JAAD Case Rep 2022; 24:64-67. [PMID: 35619593 PMCID: PMC9127529 DOI: 10.1016/j.jdcr.2022.04.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Affiliation(s)
- Richard Bindernagel
- Department of Dermatology, HCA Healthcare/USF Morsani College of Medicine GME, Largo Medical Center, Largo, Florida
- Correspondence to: Richard Bindernagel, DO, MBA, Department of Dermatology, HCA Healthcare/USF Morsani College of Medicine GME, Largo Medical Center, 201 14th St SW, Largo, FL 33770.
| | - Robert Dazé
- Department of Dermatology, HCA Healthcare/USF Morsani College of Medicine GME, Largo Medical Center, Largo, Florida
| | - Julie Gibbs
- C.W. Bill Young Department of Veterans Affairs Medical Center, Bay Pines, Florida
| | - Daniel Hogan
- C.W. Bill Young Department of Veterans Affairs Medical Center, Bay Pines, Florida
| |
Collapse
|
3
|
Fronek L, Bindernagel R, Segars K, Miller R. Multicentric reticulohistiocytosis masquerading as cutaneous connective tissue disease. Dermatol Online J 2021; 27:13030/qt37h8p3rp. [PMID: 33865276] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/12/2021] [Accepted: 04/12/2021] [Indexed: 06/12/2023] Open
Abstract
Multicentric reticulohistiocytosis (MRH) is a rare type of non-Langerhans cell histiocytosis characterized by coral-toned papules with predilection for dorsal surfaces in addition to severe arthropathy. It sometimes proves difficult to differentiate these joint and skin findings clinically from certain rheumatologic diseases, primarily dermatomyositis. Herein, we present an 82-year-old woman who presented with the clinical findings described above and was subsequently diagnosed with MRH after biopsy and review of relevant clinical history. Because about 25% of patients diagnosed with MRH have an underlying occult malignancy, our patient underwent a complete malignancy workup that was negative. She was treated with systemic corticosteroids and methotrexate, which resulted in an improvement of the arthritis and constitutional symptoms. This case demonstrates that in patients with both rheumatologic and dermatologic symptoms, particularly on acral surfaces, MRH must be a diagnostic consideration. Identifying this disease early in its course can prevent negative consequences for the patients, specifically arthritis mutilans and upper airway involvement.
Collapse
Affiliation(s)
| | | | | | - Richard Miller
- Department of Dermatology, HCA Healthcare/USF Morsani College of Medicine Largo, FL.
| |
Collapse
|
4
|
Venincasa MJ, Randlett O, Sumathipala SH, Bindernagel R, Stark MJ, Yan Q, Sloan SA, Buglo E, Meng QC, Engert F, Züchner S, Kelz MB, Syed S, Dallman JE. Elevated preoptic brain activity in zebrafish glial glycine transporter mutants is linked to lethargy-like behaviors and delayed emergence from anesthesia. Sci Rep 2021; 11:3148. [PMID: 33542258 PMCID: PMC7862283 DOI: 10.1038/s41598-021-82342-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 01/19/2021] [Indexed: 11/17/2022] Open
Abstract
Delayed emergence from anesthesia was previously reported in a case study of a child with Glycine Encephalopathy. To investigate the neural basis of this delayed emergence, we developed a zebrafish glial glycine transporter (glyt1 - / -) mutant model. We compared locomotor behaviors; dose-response curves for tricaine, ketamine, and 2,6-diisopropylphenol (propofol); time to emergence from these anesthetics; and time to emergence from propofol after craniotomy in glyt1-/- mutants and their siblings. To identify differentially active brain regions in glyt1-/- mutants, we used pERK immunohistochemistry as a proxy for brain-wide neuronal activity. We show that glyt1-/- mutants initiated normal bouts of movement less frequently indicating lethargy-like behaviors. Despite similar anesthesia dose-response curves, glyt1-/- mutants took over twice as long as their siblings to emerge from ketamine or propofol, mimicking findings from the human case study. Reducing glycine levels rescued timely emergence in glyt1-/- mutants, pointing to a causal role for elevated glycine. Brain-wide pERK staining showed elevated activity in hypnotic brain regions in glyt1-/- mutants under baseline conditions and a delay in sensorimotor integration during emergence from anesthesia. Our study links elevated activity in preoptic brain regions and reduced sensorimotor integration to lethargy-like behaviors and delayed emergence from propofol in glyt1-/- mutants.
Collapse
Affiliation(s)
- Michael J Venincasa
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA
| | - Owen Randlett
- Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, 02138, USA
- Univ Lyon, Université Claude Bernard Lyon 1, CNRS UMR 5310, INSERM U 1217, Institut NeuroMyoGène, 69008, Lyon, France
| | - Sureni H Sumathipala
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA
| | - Richard Bindernagel
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA
| | - Matthew J Stark
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA
| | - Qing Yan
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA
| | - Steven A Sloan
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA
- Department of Human Genetics, Emory University School of Medicine, Atlanta, GA, 30322, USA
| | - Elena Buglo
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA
- John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, 33101, USA
- Dr. John T. MacDonald Foundation Department of Human Genetics, University of Miami, Miami, FL, 33136, USA
| | - Qing Cheng Meng
- Departments of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Florian Engert
- Department of Molecular and Cellular Biology, Harvard University, Cambridge, MA, 02138, USA
| | - Stephan Züchner
- John P. Hussman Institute for Human Genomics, University of Miami, Miami, FL, 33101, USA
- Dr. John T. MacDonald Foundation Department of Human Genetics, University of Miami, Miami, FL, 33136, USA
| | - Max B Kelz
- Departments of Anesthesiology and Critical Care, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Pharmacology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Neuroscience, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
- Institute for Translational Medicine and Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA
| | - Sheyum Syed
- Department of Physics, University of Miami, Coral Gables, FL, 33146, USA
| | - Julia E Dallman
- Department of Biology, University of Miami, 1301 Memorial Drive, Coral Gables, FL, 33146, USA.
| |
Collapse
|
8
|
Bindernagel R, Cook C, Wayant C, Jellison S, Vassar M. Assessing the quality of intervention reporting in dermatology randomized controlled trials using the TIDieR checklist. Br J Dermatol 2020; 183:1114-1115. [PMID: 32628774 DOI: 10.1111/bjd.19382] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/26/2019] [Revised: 06/24/2020] [Accepted: 06/26/2020] [Indexed: 12/01/2022]
Affiliation(s)
- R Bindernagel
- Kansas City University of Medicine and Biosciences, Kansas City, MO, USA
| | - C Cook
- Oklahoma State University Center for Health Sciences, Tulsa, OK, USA
| | - C Wayant
- Oklahoma State University Center for Health Sciences, Tulsa, OK, USA
| | - S Jellison
- Oklahoma State University Center for Health Sciences, Tulsa, OK, USA
| | - M Vassar
- Oklahoma State University Center for Health Sciences, Tulsa, OK, USA
| |
Collapse
|
9
|
Wayant C, Bindernagel R, Vassar M. TIDieR checklist evaluation of clinical trial intervention reporting for recent FDA-approved anticancer medications. BMJ Evid Based Med 2020; 25:97-101. [PMID: 31653687 DOI: 10.1136/bmjebm-2019-111249] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 10/15/2019] [Indexed: 11/04/2022]
Abstract
IMPORTANCE Clear and comprehensive descriptions of clinical trial interventions are necessary to translate new results into clinical practice. The TIDieR checklist was developed to be a minimum set of key items considered essential to high-quality reporting of clinical trial interventions. OBJECTIVE To determine the quality of reporting of recent Food and Drug Administration (FDA)-approved oncology interventions. DESIGN Cross-sectional investigation. SETTING/PARTICIPANTS/INTERVENTION Recent, FDA-approved haematology/oncology anticancer interventions. MAIN OUTCOME MEASURE Quality of reporting. RESULTS Across all included trials (n=96), a median of 8-9 (out of 12) TIDieR items were reported. Seven TIDieR items had >90% adherence, including individual-level and study-level modifications of drugs and dosing schedules. Three items were less often reported: intervention provider, including training and expertise (7/192, 3.6%); trial institution infrastructure (0/192, 0.0%); and how intervention compliance was assessed (59/192, 30.7%). Publication of a protocol improved intervention reporting (p<0.001). CONCLUSIONS In this analysis of clinical trials of recent, FDA-approved anticancer interventions, we found good adherence to the TIDieR checklist. These studies were homogeneous in their structure and included information; some TIDieR items were always or never/rarely reported. Clinical trial effect sizes may not translate to real-world practice for a number of reasons. Thus, to aid the translation of trial effect sizes to real-world practice, we recommend authors adhere to the TIDieR checklist and describe the infrastructure of trial centres and describe who provided the intervention, along with their expertise.
Collapse
Affiliation(s)
- Cole Wayant
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| | - Richard Bindernagel
- Kansas City University of Medicine and Biosciences, Kansas City, Missouri, USA
| | - Matt Vassar
- Psychiatry and Behavioral Sciences, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA
| |
Collapse
|